The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment

Abstract

Platelet activation and aggregation are central processes in the pathophysiology of coronary heart disease. Mean platelet volume (MPV), a determinant of platelet activation, is a newly emerging risk marker for atherothrombosis. Rosuvastatin, a new hydrophilic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin), is approved as an adjunct to diet in patients with dyslipidemia. In this study, we evaluated the effects of rosuvastatin on the MPV levels in patients with uncontrolled primary dyslipidemia with hypolipidemic treatment. We selected 30 age, sex and body mass index matched patients with uncontrolled primary dyslipidemia and hypolipidemic diet treatment and 30 normolipidemic healthy subjects. Dyslipidemic patients were treated with 10 mg/day rosuvastatin for 12 weeks. Metabolic parameters and MPV were measured at baseline and after rosuvastatin treatment in dyslipidemic group. At baseline, the dyslipidemic group had significantly higher MPV levels than in the healthy control group (8.4 +/-1.2 fl vs. 8.1 +/-0 1.0 fl, p < 0.005). The level of MPV decreased significantly after rosuvastatin treatment from a mean of 8.4 +/- 1.2 fl to 8.1 +/- 1.3 fl, (p < 0.001). The changes in MPV levels with rosuvastatin treatment were not correlated to changes in plasma lipids (p > 0.05). In addition to its well-known hypolipidemic effect, rosuvastatin also possesses significant anti-platelet activation properties. This antiplatelet effect of rosuvastatin treatment could play a role in reducing cardiovascular complications in primary hyperlipidemic patients.

Platelet indices in Philadelphia-negative chronic myeloproliferative neoplasms / Indicii plachetari de volum în neoplasmele mieloproliferative cronice Philadelphia-negative

“…Bellucci et al also observed an increase in platelet volume in patients treated with anagrelide [32]. Coban et al found that treatment with rosuvastatin decreased in a significant way the MPV values [33]. In our study we found similar results in a subgroup of 13 patients who underwent treatment with simvastatin.…”

Rosuvastatin and Mean Platelet Volume in Diabetes

“…Taken together, the more recent findings 28 and those from the earlier studies suggest that rosuvastatin 23,24 and atorvastatin, 25,26 but not pravastatin, 27 exert an additional beneficial action on MPV. With rosuvastatin this action is not mediated by the improved serum lipids, 28 whereas atorvastatin achieved a significant MPV reduction in patients with the strongest concomitant lipid changes.…”

“…23,24 Of note, there was no correlation between reduction in MPV and improvement in serum lipids following treatment. 23,24 Atorvastatin can also decrease the MPV. 25,26 Of note, this beneficial effect appears to be more pronounced in patients exhibiting the strongest lipid reduction.…”

“…22 There is evidence from 2 studies that rosuvastatin administration reduces MPV. 23,24 It has been shown for the 10, 20, and 40 mg/d dosages for a follow-up period of 8 to 12 weeks. 23,24 Of note, there was no correlation between reduction in MPV and improvement in serum lipids following treatment.…”

“…23,24 It has been shown for the 10, 20, and 40 mg/d dosages for a follow-up period of 8 to 12 weeks. 23,24 Of note, there was no correlation between reduction in MPV and improvement in serum lipids following treatment. 23,24 Atorvastatin can also decrease the MPV.…”